ANGLE plc (AGL.L)

10,75 0,00 (0,00%) Börsenschluss: 04:19PM BST

ANGLE plc

Surrey Research Park
10 Nugent Road
Guildford GU2 7AF
United Kingdom
44 14 8334 3434
https://angleplc.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 150

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Andrew David William Newland ACA, Meng	Founder, CEO & Executive Director	281k	N/A	1961
Mr. Ian Francis Griffiths ACA, BA	CFO, Finance Director, Company Secretary & Executive Director	180k	N/A	1964
Mr. Martin Cooke	Director of Operations & Regulatory Affairs	N/A	N/A	1969
Dr. Karen Miller Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Andrew John Holder	Head of Investor Relations	N/A	N/A	1968
Ms. Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	N/A	N/A	N/A
Mr. Brett Swansiger	Chief Commercial Officer	N/A	N/A	N/A
Mr. Nick Claxton	Senior Vice President of Commercial Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Corporate Governance

ANGLE plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.